Sponsor Dossier
Boucher & Muir
Sponsor Dossier for Boucher & Muir. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ARX-METHOTREXATE
- Brand: BUPIVACAINE
- Brand: CLINDAMYCIN
- Brand: DESMOPRESSIN ADVZ
- Brand: EVISTA
- Brand: Ferropods
- Brand: Flecainide
- Brand: FLUTICASONE
- Device (sponsor): Pipette, single channel/multichannel, mechanical
- Device (sponsor): Blood/tissue storage/culture container
- Device (sponsor): Blood donor set, double-pack
- Device (sponsor): Blood donor set, triple-pack
About
Boucher & Muir is an Australian Private Company with ABN 58000140474, registered in New South Wales, with entity status Active. The company operates under the trading name Advanz Pharma (Australia), and has previously traded as Concordia International (Australia) and BNM GROUP.
Portfolio
Boucher & Muir holds 35 brands on the ARTG, with 27 indexable brands. The portfolio includes 27 brands with Product Information on file, 3 brands with at least one PBS-listed item, and 3 brands with PBAC outcome records. Notable brands in the portfolio include ARX-METHOTREXATE, BUPIVACAINE, CLINDAMYCIN, DESMOPRESSIN ADVZ, EVISTA, Ferropods, Flecainide, FLUTICASONE, IONIL, ISAVUCONAZOLE, METHOTREXATE ADVZ, and NIMOTOP.
Therapeutic focus —
Neurology (7 brands) — Infectious Disease (6 brands) — Pain & Anaesthesia (4 brands) — Oncology (3 brands) — Endocrinology (3 brands) — Women's Health (2 brands) — Cardiology (2 brands) — Immunology (2 brands) — Other (2 brands) — Complementary Medicine (1 brand) — Respiratory (1 brand) — Gastroenterology (1 brand) — Dermatology (1 brand)
PBS footprint
Three brands in the Boucher & Muir portfolio hold PBS-listed items, with the latest schedule date touched being 1 May 2026.
Regulatory activity
Boucher & Muir has three brands with PBAC outcomes on record, with the most recent outcome dated 1 November 2020.